In this podcast we feature an article that looks at the small molecules approved as new molecular entities thus far in 2020 and which have blockbuster potential. For the text version of this article visit dcatvci.org.

Key topics: (see Chapter Markers)

• Small-molecule new drug approvals thus far in 2020
• Small molecules and blockbuster potential
• Novo Nordisk’s Rybelsus
• Bristol-Myers Squibb’s Zeposia
• Novartis’ inclisiran
• Gilead Sciences’ filgotinib
• Akebia  Therapeutics’, Mitsubishi Tanabe Pharma’s, and Otsuka Pharmaceutical’s vadadustat
• Biohaven Pharmaceuticals’ Nurtec

 Sponsor: Dr. Reddy’s Laboratories